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Abstract
Diabetic ketoacidosis (DKA) is the most frequent hyperglycaemic acute diabetic complication. Furthermore it carries a significant risk 
of death, which can be prevented by early and effective management. All physicians, irrespective of the discipline they are working in 
and whether in primary, secondary or tertiary care institutions, should be able to recognise DKA early and initiate management 
immediately. 
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Introduction
Diabetic ketoacidosis (DKA) is a common complication of diabetes with 
an annual occurrence rate of 46 to 50 per 10 000 diabetic patients. The 
severity of this acute diabetic complication can be appreciated from the 
high death-to-case ratio of 5 to 10%.1 In Africa the mortality of DKA is 
unacceptably high with a reported death rate of 26 to 29% in studies 
from Kenya, Tanzania and Ghana.2 It is a complication of both type 1 
and type 2 diabetes mellitus, although more commonly seen in type 1 
diabetic patients. Of known diabetic patients presenting with DKA about 
one-quarter will be patients with type 2 diabetes. In patients presenting 
with a DKA as first manifestation of diabetes about 15% will be type 2.3 
This correlates well with data from South Africa suggesting that one-
quarter of patients with DKA will be type 2 with adequate C-peptide levels 
and the absence of anti-GAD antibodies.4
This review will focus on the principles of diagnosis, monitoring and 
treatment of DKA, with special mention of new developments and 
controversial issues.
Clinical features
DKA evolves over hours to days in both type 1 and type 2 diabetic 
patients, but the symptoms of poor control of blood glucose are 
usually present for several days before the onset or presentation 
of ketoacidosis.5 The clinical features of DKA are non-specific and 
patients may present with complaints of nausea, vomiting and 
weakness, polyuria, polydipsia, abdominal pain and weight loss. In a 
study by Newton and Raskin6 the frequency of symptoms in patients 
were as follows: nausea 83.4%, vomiting 78.5%, polyuria 75.2%, 
polydipsia 74.4%, abdominal pain 51.2%, weight loss 42.1% and 
polyphagia 33.1%. Abdominal pain is a misleading manifestation, 
which can result in the late or misdiagnosis of DKA. Abdominal pain 
appears to be related to the presence of metabolic acidosis, but 
the exact mechanism is poorly understood.7 Often in children the 
abdominal pain may clinically mimic the findings of an acute abdomen.
Physical examination may also show evidence of dehydration: loss of 
skin turgor, dry mucus membranes, tachycardia and hypotension.5 In 
the study by Newton and Raskin,6 patients had an average heart rate of 
117 beats per minute, but most patients had a slightly elevated systolic 
and diastolic blood pressure (mean 135 ± 23 and 85 ± 15). Most 
patients were normothermic or hypothermic despite the high frequency 
of infection present and it seems that severe hypothermia carries a 
poor prognosis.5 Patients with DKA can present with varying levels of 
consciousness with the majority of patients being alert and less than 
20% present comatose.8 Abnormalities detected in mental status 
examination seem to correlate best with an increase in osmolality. 
Furthermore, patients with severe metabolic acidosis will usually have 
distinctively rapid and deep breathing (Kussmaul’s breathing).
Diagnostic criteria
In 2003 the American Diabetes Association (ADA) modified the 
diagnostic criteria of DKA with the introduction of severity categories of 
mild, moderate and severe (see Table I).
Table I: Diagnostic criteria and severity of DKA
Mild Moderate Severe
Plasma glucose (mmol/L) > 13.9 > 13.9 > 13.9
Arterial pH 7.25–7.30 7.00–7.24 < 7.00
Serum bicarbonate 
(mmol/L) 15–18 10–14.9 < 10
Urine ketones Positive Positive Positive
Serum ketones Positive Positive Positive
Anion gap > 10 > 12 > 12
Sensorium Alert Alert/drowsy Stupor/coma
Adapted from ADA position statement 9
The diagnosis of DKA consists of a triad of hyperglycaemia, 
ketonaemia and metabolic acidosis.10 
Most DKA guidelines indicate that hyperglycaemia of more than 13.9 
mmol/l is necessary for the diagnosis of DKA , however this is not 
an absolute requirement, as DKA without hyperglycaemia has been 
reported. DKA without hyperglycaemia is mostly reported during 
pregnancy, and in patients with prolonged vomiting or starvation. It can 
also occur in patients with liver failure or in alcohol abusers.11
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Ketone bodies are produced in the liver from acetyl-CoA liberated 
during lipolysis from fatty acids. For DKA to develop, an absolute or 
relative insulin deficiency must be present. Three ketone bodies are 
produced: acetone (resulting in the fruity odour of DKA patients), 
aceto-acetate and β-hydroxybuterate (β-OHB). β-OHB is the most 
prominent contributor to metabolic acidosis in patients with DKA. 
Acetone does not contribute to acidosis and is not usually measured 
as such. Aceto-acetate can be measured in the urine with a urine 
dipstick utilising the nitroprusside reaction. As DKA resolves, β-OHB 
are oxidised to acetoacetate. Therefore, if only a urine ketone dipstick 
procedure is done it might give the impression that the condition 
is not improving. Currently blood ketones can be measured with a 
point of care (bedside) meter utilising capillary finger prick blood.12 
This measures β-OHB directly and accurately.13,14 A capillary β-OHB 
value of 3 mmol/l and above has a positive likelihood ratio of 15 for 
the presence of DKA.15 It is recommended by the ADA that the blood 
ketone measurement of β-OHB is preferable to urine measurement for 
the diagnosis and monitoring of DKA.9
An arterial pH of less than 7.3 should be present in the diagnosis of 
DKA. The measurement of pH and/or serum bicarbonate is essential 
for the diagnosis and estimation of severity of DKA. The pH is also 
an important measure to assess improvement and for adjustment of 
treatment. A venous pH determination would probably be sufficient, 
unless respiratory function needs to be assessed as well. The venous 
pH is on average 0.03 lower than the arterial pH.16
Precipitating events that can trigger DKA
The most common precipitating event for the development of DKA 
is infection, which accounts for 28 to 45% of cases. Pneumonia 
or any lung disease that can influence oxygenation, and can lead 
to respiratory failure, should always be considered as extremely 
serious because it may impair respiratory compensation of metabolic 
acidosis.17 The second most common precipitating event worldwide 
is the omission of insulin.18 The third most common cause is the first 
manifestation of new onset diabetes. Other common precipitating 
events include cardiovascular events such as a stroke, myocardial 
infarction and peripheral vascular disease with gangrene.19,20 In a 
Kenyan study,21 34% of DKA events were due to missed insulin 
injections, 23.4% to overt infection and only 6.4% had both infection 
and missed insulin injections. Infection sites included respiratory, 
genito-urinary and septicaemia. DKA is about 10 times more common 
in patients with schizophrenia. This may be due to the use of the newer 
antipsychotic agents clozapine and olanzapine.22, 23
The physician caring for diabetic patients should enquire and be aware 
of the high risk related to psychological and socioeconomic factors. 
A study of urban African Americans24 states that 50% of patients 
presenting with DKA as a result of non-compliance of insulin did so 
because of lack a of money to buy insulin or to pay for transport to 
the hospital. Another 14% failed to comply with the prescribed insulin 
injections due to behavioural or psychological reasons. All diabetic 
patients should be educated and trained about what to do when they 
become ill, until they are able to see a health care professional.25
Monitoring to recovery of DKA
Due to the seriousness and high risk of relapse or deterioration in 
patients with DKA, it is important to monitor progress frequently. 
Monitoring should include clinical parameters such as blood pressure, 
pulse rate, hydration status and mental status. Laboratory and 
bedside biochemical measurements should be assessed regularly. 
These include capillary blood glucose, urine or blood ketones, serum 
potassium, sodium, phosphate and, very importantly, venous pH.26 For 
a suggested monitoring schedule please see Table II.
DKA is considered resolved when the blood glucose is less than 11.1 
mmol/l and the serum bicarbonate above 18 mmol/l or the venous pH 
is greater than 7.3. Note that the clearance of serum or urine ketones 
takes longer to resolve than the blood glucose and the pH.26,27
The indicators of recovery in most institutions are a pH greater than 
7.3 and urine ketone-free. Evidence is accumulating to utilise point-of-
care β-OHB determinations less than 1 mmol/l, on two occasions, as 
indicator of recovery, which seems to occur significantly earlier than 
urine ketone clearance.28
Table II:  Suggested frequencies of monitoring of laboratory and bedside 
parameters
Monitoring parameter Suggested frequency
Blood glucose
Hourly until blood glucose less than 14 mmol/l
Thereafter two- to four-hourly 
Once the patient is off an insulin infusion and 
eating: meal-related monitoring (before each 
meal and two hours afterwards)26,29,30
Electrolytes and venous 
pH or bicarbonate Two- to four-hourly
26,29,30
Urine or blood ketones Two- to four-hourly29,30
Blood urea and creatinine Six- to eight-hourly29,30
Serum magnesium and 
phosphate Two- to four-hourly
29,30
Novel ways to monitor patients with DKA include continuous non-
invasive measurement of end-tidal CO2. This was used in two 
paediatric studies, which seemed to give an accurate estimate of 
the PCO2 and correlated well with venous pH. Capnometry therefore 
allows the clinician to have a continuous, indirect indication of the 
acidic state of patients with DKA.31,32 The CO2 can also be continuously 
measured transcutaneously.33
A frequently encountered problem is to decide where to manage a 
patient with DKA. The ADA hospital admission guidelines for diabetes 
advise admission to hospital when the plasma glucose concentration 
is 14 mmol/l or more, the pH is less than 7.3 or the serum bicarbonate 
less than 15 mmol/l in the presence of moderate amounts of ketones 
in the blood or urine.34 These guidelines also suggest ICU admission in 
cases of severe DKA. In a survey on treatment of DKA in Denmark, it 
was found that in one-third of institutions DKA is routinely managed in 
ICU.35 This is also the case in the United States, where hospital policy 
dictates that insulin may only be administered intravenously in an 
ICU.2,36 In a setting with limited resources, ICU or high-care admission 
is frequently not an option, but a higher level of care is needed for 
patients with DKA due to the need for frequent monitoring and the 
complexity of treatment regimens. This requires a team approach of 
dedicated nursing and medical ward staff.
Treatment of DKA
The management of DKA is multifaceted and therefore requires a 
structured approach by clinicians and nurses. Numerous treatment 
guidelines are available in the medical literature; however, these are 
not always rigorously followed. In a Scottish study in an academic 
institution, delays in the initiation of intravenous (IV) fluid replacement 
and administration of insulin were seen in up to 70% of cases. Under-
replacement of IV fluids and inadequate potassium replacement during 
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the first 24 hours were seen in 70% of cases. These inadequacies 
occurred despite the availability of treatment guidelines.37 Every 
hospital managing patients with DKA should have a structured way or 
a so-called integrated care pathway for managing patients with DKA. 
This is a detailed management plan that should dictate the sequence 
and timing of actions, and specify by whom it should be done, in 
order to fulfil the goals of treatment. A recent study showed that an 
integrated care pathway improves key areas in the management of 
DKA significantly.38
Fluid replacement
The fluid deficit is typically about 100 ml/kg body weight, which 
amounts to five to seven litres in the average adult patient.26,27 The 
deficit can be calculated using the following formulas: 
Fluid deficit = (0.6xbody weight in kg)x(corrected Na+/140)
Corrected Na+ = sNa+ + (sGlucose - 5)/3.5
Administration of fluids alone results in a significant fall in blood 
glucose levels. This is mediated by recovery of the glomerular filtration 
rate, which declines with severe dehydration caused by the DKA.39 
All the guidelines recently published and accessed by the author 
recommend the use of 0.9% NaCl solution as initial resuscitation fluid 
or the use of 0.45% NaCl solution if the serum sodium concentration is 
high.4,19,26,27,40,41 No randomised controlled trials are currently available 
to support the superiority of any specific fluid regimen.40 The use of 
Ringer’s lactate solution is advocated in some units based on the 
strong-ion theory for acidosis (Stewart’s hypothesis). Currently no 
definitive proof based on randomised controlled trials are available 
to assume that there is any benefit in using Ringer’s lactate solution 
instead of a saline-based regimen. Some guidelines do allow for the 
use of Ringer’s lactate after initial resuscitation.40
Fluid resuscitation should be aggressive with the administration of 1 to 
1.5 l of fluid within the first hour and thereafter 250 to 500 ml/hour.5,42 
The aim is to replace 50% of the fluid deficit within the first 8 to 12 
hours and the rest within the next 12 to 16 hours.26 Once the blood 
glucose drops below 14 mmol/l, it is generally advised to change 
the fluid administration to a dextrose-containing solution (either 5% 
dextrose water or 5% dextrose in 0.9% NaCl solution or 5% dextrose 
in 0.45% NaCl solution).5,26,27,41 In elderly patients or patients with 
cardiovascular, renal or liver disease, be careful for overhydration and 
volume overload. It is usually beneficial in these patients to monitor 
fluid administration invasively with a central venous line.43
Insulin therapy
Low dose (0.1 U/kg/hour) IV administration of soluble insulin is 
currently the standard of care in patients with DKA.44,45 Soluble insulin 
(regular, lispro or aspart) should be used, but it should be noted that 
the synthetic insulins do not work faster than regular insulin when 
administered intravenously.19 Before commencing insulin therapy, 
hypokalaemia (sK+ < 3.3 mmol/l) should be excluded. Insulin should be 
initiated with an IV bolus of 0.1 to 0.15 U/kg followed by a continuous 
infusion of  0.1 U/kg/hour. Children should not receive an insulin bolus 
since it may increase the risk of cerebral edema.46 Adjust the insulin 
infusion rate to maintain a steady decrease in blood glucose of 3 to 5 
mmol/l/hour.5,19 Once blood glucose is lower than 9 mmol/l, the infusion 
rate can be decreased.5,26
After resolution of DKA, the patient can be started on a multidose 
insulin regimen with regular or rapid-acting insulin for prandial 
requirements and intermediate or long-acting insulin for basal 
requirements. The insulin infusion should be stopped one to two hours 
after the first subcutaneous insulin injection. Patients who were on 
insulin therapy before the onset of the DKA can be restarted on their 
usual insulin regimen. The usual starting dose for patients who were 
not on insulin before is 0.5 to 0.6 U/kg/day.5,19,30,40
Two clinical trials have been done to assess the use of rapid acting 
insulin analogues subcutaneously in patients with DKA.47,48 Although 
these were small studies, no statistical difference in outcomes could be 
demonstrated between patients receiving subcutaneous rapid-acting 
insulin analogues and those receiving regular insulin infusions. The 
analogues were administered as an initial bolus of 0.3 U/kg, which was 
followed by 0.1 U/kg every hour until the blood glucose was less than 
14 mmol/l, when the dosage was halved to 0.05 U/kg/h.
Potassium replacement
Total body potassium is depleted in DKA. This occurs in spite of 
a normal, high or a low serum potassium concentration. Volume 
increase during rehydration, insulin therapy and recovery of acidosis 
all mediate a drop in potassium concentration, which may lead to 
severe hypokalaemia with cardiac arrhythmias or respiratory muscle 
weakness. Therefore potassium needs to be replaced even if the 
concentration is still normal. Initiate potassium supplementation if the 
serum potassium is 3.3–5.3 mmol/l, and monitor it regularly.5,26
Bicarbonate 
The administration of bicarbonate in patients with DKA is controversial. 
Prospective trials have indicated that no benefit or harm is associated 
with the administration of bicarbonate in patients with DKA who have 
a pH 6.9 to 7.1.49 No information is available for potential benefits of 
bicarbonate administration in patients with a pH less than 6.9. Some 
published DKA guidelines recommend the use of bicarbonate if the pH 
is less than 7.5,10 Others do not recommend the use of bicarbonate at 
all, unless cardiogenic shock or other lactate-generating conditions are 
present.41
Phosphate replacement
The total body phosphate is depleted in patients with DKA, but as in 
the case of potassium the serum concentration is frequently normal 
or high at presentation. With treatment of DKA and especially insulin 
administration the phosphate concentration may drop significantly. 
Studies evaluating the routine administration of phosphate in DKA 
patients did not show any benefit.50 However, a very low phosphate 
concentration may result in muscle weakness and respiratory 
depression and for this reason phosphate should be replaced if the 
serum phosphate is less than 0.33 mmol/l.
DKA in special populations
Although the pathophysiology of DKA is essentially the same in 
children, adolescents, the elderly as well as during pregnancy, each of 
these special populations have their specific nuances. 
Children
Due to the inability of infants and small children to give a history of the 
symptoms of diabetes, DKA is often misdiagnosed at first presentation 
as pneumonia or bronchiolitis. The diagnosis is often made late. At 
diagnosis patients are frequently severely dehydrated, have severe 
acidosis and are often unconscious. Children require a more precise 
calculation and replacement of fluid losses because of changes in 
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body surface area in relationship to mass as the child grows older.51 
The cerebral autoregulatory mechanism in younger children is less well 
developed which, in conjunction with greater severity of DKA, results 
in a much higher frequency of cerebral oedema in up to 1% of all DKA 
cases.30,46 
Adolescents
The major problem in this patient group is neglect on the part of 
patients to take insulin with serious lapses in patient adherence to 
treatment. These patients need to be seen in conjunction with their 
families, and long-term psychological support may be needed to 
prevent repeated DKA episodes. In this patient group, 5% of patients 
are responsible for more than 25% of DKA admissions.30,52
The elderly
Comorbid conditions play an important role in elderly patients. It 
predisposes them to DKA and a poorer outcome of DKA. Important 
precipitating conditions that need to be considered in elderly patients 
with DKA are myocardial infarctions, stroke and infections.53 In a UK 
study females older than 59 years of age were identified as a high-risk 
group for recurrent DKA due to other chronic diseases complicating the 
diabetes.54
During pregnancy
During pregnancy not only the mother is significantly affected by the 
development of DKA. The perinatal mortality related to DKA is between 
9 and 35%.55,56 DKA during pregnancy results in reduced oxygenation 
of the feto-placental unit due to reduced uterine blood flow and a 
left shift in the haemoglobin dissociation curve (increased affinity of 
haemoglobin for oxygen).57 During DKA foetal distress is frequently 
observed, but intervention for foetal compromise should be delayed 
until the mother is properly resuscitated, because this frequently 
reverses foetal distress.58
Complications of DKA
DKA and the management thereof occur frequently and can to a large 
extent be prevented if management and monitoring is optimal. The 
most common complications are hypoglycaemia,8 hypokalaemia,5 
relapses of DKA and, in children, cerebral oedema. 47
Conclusion
DKA is a common and severe complication of diabetes mellitus that 
occurs in both type 1 and type 2 diabetic patients. It is to a large extent 
preventable if the proper patient education, training on how to manage 
sick days and when to contact a health care provider are introduced. 
Patients should know the importance of using insulin and the significant 
dangers if use is neglected. Patients’ families should be educated to 
identify acute diabetes complications so that immediate measures can 
be instituted. Physicians and other health care professionals should 
be vigilant to identify high-risk patients and timely institute measures to 
prevent the development of severe hyperglycaemic complications.  
Table III: Summary of management of DKA in adults







1 to 1.5 litre in the first hour 
(infusion rate: 15–20 ml/kg)
IV bolus:
Regular insulin 0.1–0.15 IU/kg followed by a 
continuous infusion at a rate of 0.1 IU/kg per hour
Usually prepared as follows: 20 IU in 200 ml 0.9% 
saline (0.1 IU/ml) 
Thus for an 80 kg person: 8 IU/h = 80 ml/h or 80 
microdrops/min
Reassess blood glucose
Increase the insulin infusion rate if the blood 
glucose concentration does not decrease by 3 to 
4 mmol/l/h
Adjust infusion rate two-hourly based on blood 
glucose as follows:
•  s Glucose: < 5.6 mmol/l decrease by 10 ml/h 
and give 
25 ml of 50% dextrose IV
•  s Glucose: 5.6–8.9 mmol/l decrease by 10 
ml/h (1 IU/h)
• s Glucose: 9–12.2 mmol/l no change
•  s Glucose: 12.3–15.6 mmol/l increase by 10 
ml/h (1 IU/h)
•  s Glucose > 15.6 mmol/l increase by 10 ml/h 
and give a bolus of regular insulin of 8 U IV 
When the patient is able to eat, give meal-related 
boluses of regular insulin (usually 1 IU per 
15 g carbohydrate in meal), in addition to the 
continuous IV insulin infusion
Bicarbonate
(Controversial)
If the pH < 7.0:
50 mmol/l NaHCO3 in 200 ml 0.45% saline over 
one hour
If the pH < 6.9:
100 mmol/l NaHCO3 in 400 ml 0.45% saline over 
one hour
This can be repeated two-hourly
Potassium
Always check K+ concentration before 
commencing with insulin administration.
•  If sK+ > 5.0 mmol/l no K+ supplement but 
check q two-hourly
•  If sK+ 3.0 – 5.0 mmol/l add 20 mmol in each 
litre of IV fluid in order to maintain the sK+ 
concentration between 4.0–5.0 mmol/l
•  If sK+ < 3.0 mmol/l add 40 mmol to the initial 
IV fluid (withhold insulin untill K+ > 3.0 mmol/l)
Phosphate
Replacement only necessary if PO4 concentration 
is < 0.33 mmol/l. Replace with potassium 










Continue with 0.9% NaCl if sNa is normal or low: 
250–500 ml/h 
(4–14 ml/kg depending on the hydration status)
If sNa+ is elevated change to 0.45% NaCl
Replace half the fluid deficit in the first 12 hours
















Change to 5% dextrose or 5% dextrose in 0.45% 
NaCl solution
Adapted from Rheeder and Oosthuizen, JEMDSA 2004;9(1):22–4. 43
CPD Article
SA Fam Pract 2008                  Vol 50 No 138
CPD Article
SA Fam Pract 2008                  VOL. 50, No139
References
1.  Faich GA, Fishbein HA, Ellis SE. The epidemiology of diabetic acidosis: A population-
based study. American Journal of Epidemiology 1983;117(5):551–8.
2.  Otieno CF, Kayima JK, Omonge EO, Oyoo GO. Diabetic ketoacidosis: Risk factors, 
mechanisms and management strategies in sub-Saharan Africa: A review. East African 
Medical Journal 2005; 82 (12 Suppl):S197–203.
3.  Newton CA, Rashkin P. Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus. 
Clinical and biochemical differences. Arc Intern Med 2004;164:1925–31.
4.  Rheeder P, Stolk RP, Grobbee DE. Ethnic differences in C-peptide levels and anti-GAD 
antibodies in South African patients with diabetic ketoacidosis. Q J Med 2001;94:
39–43.
5.  Kitabachi AE, Murphy MB, Umpierrez GE, Kreisberg RA. Hyperglycemic crisis in 
patients with diabetes mellitus. Position statement. Diabetes Care 2006;29(12):
2739–48.
6.  Newton CA, Rashkin P. Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus. 
Clinical and biochemical differences. Arch Intern Med 2004;164:1925–31.
7.  Umpierrez G, Freire AX. Abdominal pain in patients with hyperglycaemic crises.   J Crit 
Care 2002;17:63–7.
8.  Umpierrez GE, Kelly JP, Navarrete JE, Casals MM, Kitabchi AE. Hyperglycemic crisis 
in urban blacks. Arch Intern Med 1997;157:669–75.
9.  American diabetes association. Hyperglycemic crises in patients with diabetes mellitus. 
Diabetes Care 2003;26 (Suppl 1):S109–17.
10.  American diabetes association. Hyperglycemic crises in diabetes. Diabetes Care 
2004;27 (Suppl 1):S94–102.
11.  Jenkins D, Close CF, Krentz AJ, Nattrass M, Wright AD. Euglycaemic diabetic 
ketoacidosis: Does it exist? Acta Diabetologica 1993;30(4):251–3.
12.  Sacks DB, Burns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. 
Guidelines and recommendations for laboratory analysis in the diagnosis and 
management of diabetes mellitus. Clinical Chemistry 2002;48(3):436–72.
13.  Meas T, Taboulet P, Sobngwi E, Gautier JF. Is capillary ketone determination useful in 
clinical practice? In which circumstances? Diabetes Metab 2005;31:299–303.
14.  Guerci B, Tubiana-Rufi N, Bauduceau B, Bresson R, Cuperlier A, Delcroix C, et al. 
Advantages to using capillary blood ε-hydroxybuterate determination for the detection 
and treatment of diabetic ketosis. Diabetes Metab 2005;31:401–6.
15.  Taboulet P, Hass H, Porcher R, Manamani J, Fontaine JP, Feugeas JP, et al. Urinary 
acetoacetate or capillary β-hydroxybuterate for the diagnosis of ketoacidosis in the 
emergency department setting. Eur J of Emerg Med 2004;11:251–8.
16.  Kreshak A, Chen EH. Arterial blood gas analysis: Is its value needed for the 
management of diabetic ketoacidosis? Ann of Emerg Med 2005;45(5):550–1.
17.  Carroll P.  Matz R. Adult respiratory distress syndrome complicating severely 
uncontrolled diabetes mellitus: Report of nine cases and a review of the literature. 
Diabetes Care 1982;5(6):574–80.
18.  Morris AD, Boyle DI, McMahon AD, Greene SA, MacDonald TM, Newton RW. 
Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-
dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and 
Research in Tayside Scotland. Medicines Monitoring Unit. Lancet1997;350(9090):
1505–10.
19.  Trachtenbarg DE. Diabetic ketoacidosis. American Family Physician 2005;71(9):
1705–14.
20.  Basu A, Close CF, Jenkins D, Krentz AJ, Nattrass M, Wright AD. Persisting mortality in 
diabetic ketoacidosis. Diabetic Medicine 1993;10(3):282–4.
21.  Mbugua PK, Otieno CF, Kayima JK, Amayo AA, McLigeyo SO. Diabetic ketoacidosis: 
Clinical presentation and precipitating factors at Kenyatta National Hospital, Nairobi. 
East African Medical Journal 2005; 82 (12 Suppl):S191–6.
22.  Henderson DC, Cagliero E, Copeland PM, Louie PM, Borba CP, Fan X, et al. Elevated 
hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis 
in schizophrenia patients receiving atypical antipsychotics. Journal of Clinical 
Psychiatry 2007;68(4):533–41.
23.  Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes 
mellitus and diabetic ketoacidosis associated with atypical antipsychotics: An analysis 
of 45 published cases. Annals of Clinical Psychiatry 2002;14(1):59–64.
24.  Musey VC, Lee JK, Crawford R, Klatka MA, McAdams D, Phillips LS. Diabetes in 
urban African-Americans. Cessation of insulin therapy is the major precipitating cause 
of diabetic ketoacidosis. Diabetes Care 1995;18(4):483–9.
25.  Laffel LM, Wentzell K, Loughlin C, Tovar A, Moltz K, Brink S. Sick day management 
using blood 3-hydroxybutyrate (3-OHB) compared with urine ketone monitoring 
reduces hospital visits in young people with T1DM: A randomized clinical trial. Diabetic 
Medicine 2006;23(3):278–84.
26.  Eledrisi MS, Alshanti MS, Shah MF, Brolosy B, Jaha N. Overview of the diagnosis 
and management of diabetic ketoacidosis. American Journal of the Medical Sciences 
2006;331(5):243–51.
27.  Wallace TM, Matthews DR. Recent advances in the monitoring and management of 
diabetic ketoacidosis. Qjm 2004;97(12):773–80.
28.  Noyes KJ, Crofton P, Bath LE, Holmes A, Stark L, Oxley CD, et al. Hydrxybuterate 
near-patients testing to evaluate a new endpoint for intravenous insulin therapy in the 
treatment of diabetic ketoacidosis in children. Pediatric Diabetes 2007;8(3):150–6.
29.  Wolfsdorf J, Craig ME, Daneman D, Dunger D, Edge J, Lee WRW, et al. Diabetic 
ketoacidosis, ISPAD clinical practice consensus guiedelines 2006–2007. Pediatric 
Diabetes 2007;8:20–43.
30.  Wolfsdorf J, Glaser N, Sperling MA. Diabetic ketoacidosis in infants, children, and 
adolescents: A consensus statement from the American Diabetes Association. 
Diabetes Care 2006;29(5):1150–9.
31.  Agus MS, Alexander JL, Mantell PA. Continuous non-invasive end-tidal CO2 
monitoring in pediatric inpatients with diabetic ketoacidosis. Pediatric Diabetes 
2006;7(4):196–200.
32.  Garcia E, Abramo TJ, Okada P, Guzman DD, Reisch JS, Wiebe RA. Capnometry 
for noninvasive continuous monitoring of metabolic status in pediatric diabetic 
ketoacidosis. Critical Care Medicine 2003;31(10):2539–43.
33.  McBride ME, Berkenbosch JW, Tobias JD. Transcutaneous carbon dioxide monitoring 
during diabetic ketoacidosis in children and adolescents. Paediatric Anaesthesia 
2004;14(2):167–71.
34.  American Diabetes Association. Hospital admission guidelines for diabetes. Diabetes 
Care 2004; 27 (Suppl 1): S103.
35.  Henriksen OM, Prahl JB, Roder ME, Svendsen OL. Treatment of diabetic ketoacidosis 
in adults in Denmark: A national survey. Diabetes Research & Clinical Practice 
2007;77(1):113–9.
36.  Haas RM, Hoffman AR. Treatment of diabetic ketoacidosis: Should mode of insulin 
administration dictate use of intensive care facilities? American Journal of Medicine 
2004;117(5):357–8.
37.  Singh RK, Perros P, Frier BM. Hospital management of diabetic ketoacidosis: Are 
clinical guidelines implemented effectively? Diabetic Medicine 1997;14(6):482–6.
38.  Waller SL, Delaney S, Strachan MW. Does an integrated care pathway enhance the 
management of diabetic ketoacidosis? Diabetic Medicine 2007;24(4):359–63.
39.  Owen OE, Licht JH, Sapir DG. Renal function and effects of partial rehydration during 
diabetic ketoacidosis. Diabetes 1981;30(6):510–8.
40.  Dunger DB, Sperling MA, Acerini CL, Bohn DJ, Daneman D, Danne TP, et al. 
European Society for Paediatric Endocrinology, Lawson Wilkins Pediatric Endocrine 
Society. European Society for Paediatric Endocrinology/Lawson Wilkins Pediatric 
Endocrine Society consensus statement on diabetic ketoacidosis in children and 
adolescents. Pediatrics 2004;113(2):e133–40.
41.  Protocol for the acute management of diabetic ketoacidosis in adults. 2005. Available 
www.diabetesinscotland.org/diabetes/maintainpages/pdffiles/DKA_protocol.pdf/. 
(Accessed 20/09/2007).
42.  Chiasson JL, Aris-Jilwan N, Belanger R, Bertrand S, Beauregard H, Ekoe JM, et al. 
Diagnosis and treatment of diabetic ketoacidosis and the hyperglycemic hyperosmolar 
state. Canadian Medical Association Journal 2003;168(7):859–66.
43.  Rheeder P, Oosthuizen H. Treatment of hyperglycaemic emergencies, 2004: The 
Pretoria approach. JEMDSA 2004;9(1):22–4.
44.  Burghen GA, Etteldorf JN, Fisher JN, Kitabchi AQ. Comparison of high-dose and low-
dose insulin by continuous infusion in the treatment of diabetic ketoacidosis in children. 
Diabetes Care 1980;3:15–20.
45.  Alberti KG. Low-dose insulin in the treatment of diabetic ketoacidosis. Arch Intern Med 
1977;137:1367–76.
46.  Edge JA, Jakes RW, Roy Y, Hawkins M, Winter D, Ford-Adams ME, et al. The UK 
case-control study of cerebral oedema complicating diabetic ketoacidosis in children. 
Diabetologia 2006;49(9):2002–9.
47.  Umpierrez GE, Latif K, Stoever J, Cuervo R, Park L, Freire AX, et al. Efficacy of 
subcutaneous insulin lispro versus continuous intravenous regular insulin for the 
treatment of patients with diabetic ketoacidosis. American Journal of Medicine 
2004;117(5):291–6.
48.  Umpierrez GE, Cuervo R, Karabell A, Latif K, Freire AX, Kitabchi AE. Treatment of 
diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care 2004;27(8):
1873–8.
49.  Morris LR, Murphy MB, Kitabchi AE. Bicarbonate therapy in severe diabetic 
ketoacidosis. Annals of Internal Medicine 1986;105(6):836–40.
50.  Fisher JN, Kitabchi AE. A randomized study of phosphate therapy in the treatment 
of diabetic ketoacidosis. Journal of Clinical Endocrinology & Metabolism 1983;57(1):
177–80.
51.  Levy-Marchal C, Papoz L, De Beaufort C, Doutreix J, Froment V, Voirin J, et al. Clinical 
and laboratory features of type 1 diabetic children at the time of diagnosis. Diabet Med 
1992;9:279–84.
52.  Ellis DA, Templin T, Naar-King S, Frey MA, Cunningham PB, Podolski CL, et al. 
Multisystemic therapy for adolescents with poorly controlled type I diabetes: Stability 
of treatment effects in a randomized controlled trial. Journal of Consulting & Clinical 
Psychology 2007;75(1):168–74.
53.  Basu A, Close CF, Jenkins D, Krentz AJ, Nattrass M, Wright AD. Persisting mortality in 
diabetic ketoacidosis. Diabetic Medicine 1993;10(3):282–4.
54.  Chapman J, Wright AD, Nattrass M, FitzGerald MG. Recurrent diabetic ketoacidosis. 
Diabetic Medicine 1988;5(7):659–61.
55.  Chauhan SP, Perry KG Jr, McLaughlin BN, Roberts WE, Sullivan CA, Morrison JC. 
Diabetic ketoacidosis complicating pregnancy. Journal of Perinatology 1996;16(3 Pt 1):
173–5.
56.  Kilvert JA, Nicholson HO, Wright AD. Ketoacidosis in diabetic pregnancy. Diabetic 
Medicine 1993;10(3):278–81.
57.  Ramin KD. Diabetic ketoacidosis in pregnancy. Obstetrics & Gynecology Clinics of 
North America 1999;26(3):481–8.
58.  Hagay ZJ, Weissman A, Lurie S, Insler V. Reversal of fetal distress following intensive 
treatment of maternal diabetic ketoacidosis. American Journal of Perinatology 
1994;11(6):430–2.
